share_log

T2 Biosystems | 8-K: Current report

T2 Biosystems | 8-K: Current report

T2 Biosystems | 8-K:重大事件
美股SEC公告 ·  2024/11/08 09:35

Moomoo AI 已提取核心訊息

On November 7, 2024, T2 Biosystems received a delisting determination from Nasdaq as the company's market value of listed securities fell below the minimum requirement of $35 million for 30 consecutive trading days. Under the terms of the previously imposed Mandatory Panel Monitor, Nasdaq did not grant a grace period.The company plans to request a hearing before the Nasdaq Hearings Panel and pay a $20,000 non-refundable fee, which will stay any delisting action pending the Panel's decision. The company's common stock will continue trading on Nasdaq during this process.However, there is no guarantee that the Panel will grant T2 Biosystems' request for continued listing or that the company will meet all applicable listing criteria within any extension period that may be granted.
On November 7, 2024, T2 Biosystems received a delisting determination from Nasdaq as the company's market value of listed securities fell below the minimum requirement of $35 million for 30 consecutive trading days. Under the terms of the previously imposed Mandatory Panel Monitor, Nasdaq did not grant a grace period.The company plans to request a hearing before the Nasdaq Hearings Panel and pay a $20,000 non-refundable fee, which will stay any delisting action pending the Panel's decision. The company's common stock will continue trading on Nasdaq during this process.However, there is no guarantee that the Panel will grant T2 Biosystems' request for continued listing or that the company will meet all applicable listing criteria within any extension period that may be granted.
2024年11月7日,T2 Biosystems收到了納斯達克的退市決定,因爲該公司的上市證券市場價值在連續30個交易日內低於3500萬美元的最低要求。根據之前實施的強制性小組監控條款,納斯達克未授予寬限期。該公司計劃請求納斯達克聽證小組舉行聽證會,並支付2萬美元的不可退還費用,這將暫停任何退市行動,直到小組做出決定。在此過程中,該公司的普通股將繼續在納斯達克交易。然而,小組是否會批准T2 Biosystems繼續上市的請求,或公司是否會在可能獲得的任何延長期內滿足所有適用的上市標準,並不能得到保證。
2024年11月7日,T2 Biosystems收到了納斯達克的退市決定,因爲該公司的上市證券市場價值在連續30個交易日內低於3500萬美元的最低要求。根據之前實施的強制性小組監控條款,納斯達克未授予寬限期。該公司計劃請求納斯達克聽證小組舉行聽證會,並支付2萬美元的不可退還費用,這將暫停任何退市行動,直到小組做出決定。在此過程中,該公司的普通股將繼續在納斯達克交易。然而,小組是否會批准T2 Biosystems繼續上市的請求,或公司是否會在可能獲得的任何延長期內滿足所有適用的上市標準,並不能得到保證。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息